Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

Despite more than 25 years of research, the molecular targets of quinoline-3-carboxamides have been elusive although these compounds are currently in Phase II and III development for treatment of autoimmune/inflammatory diseases in humans. Using photoaffinity cross-linking of a radioactively labelle...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Per Björk, Anders Björk, Thomas Vogl, Martin Stenström, David Liberg, Anders Olsson, Johannes Roth, Fredrik Ivars, Tomas Leanderson
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2009
Materias:
Acceso en línea:https://doaj.org/article/d9b0cf5ec37a4cefa5970058e75fe613
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!